Free Trial

CSL (CSLLY) Stock Forecast & Price Target

CSL logo
$67.87 -0.81 (-1.17%)
As of 11:17 AM Eastern

CSL - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
0
Buy
1

Based on 2 Wall Street analysts who have issued ratings for CSL in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a strong buy rating for CSLLY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CSLLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CSL and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CSLLY Analyst Ratings Over Time

TypeCurrent Forecast
10/6/24 to 10/6/25
1 Month Ago
9/6/24 to 9/6/25
3 Months Ago
7/8/24 to 7/8/25
1 Year Ago
10/7/23 to 10/6/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingModerate BuyStrong BuyStrong BuyStrong Buy

CSLLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CSLLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CSL Stock vs. The Competition

TypeCSLMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted UpsideN/A1,401.70% Upside168.87% Upside
News Sentiment Rating
Neutral News

See Recent CSLLY News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/15/2025Zacks Research
0 of 5 stars
 DowngradeHoldStrong Sell
1/16/2025The Goldman Sachs Group
3 of 5 stars
D. Thillainathan
Not Rated
UpgradeStrong-Buy
8/13/2024Macquarie
3 of 5 stars
D. Bailey
Not Rated
UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:06 PM ET.


Should I Buy CSL Stock? CSLLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 2, 2025. Please send any questions or comments about these CSL pros and cons to contact@marketbeat.com.

CSL
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CSL Limited:

  • The current stock price is around $67, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • CSL Limited has seen a significant decrease in short interest, indicating growing investor confidence and potentially less volatility in the stock price.
  • The company operates in multiple high-demand markets, including biopharmaceuticals and vaccines, which are critical in the current global health landscape.
  • CSL Limited has a strong financial position, with a debt-to-equity ratio of 0.50, suggesting a balanced approach to leveraging and financial stability.
  • With a diverse product portfolio across its segments, including plasma products and gene therapies, CSL Limited is well-positioned for growth in various therapeutic areas.

CSL
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CSL Limited for these reasons:

  • The stock has experienced a decline from its 12-month high of $101.44, which may raise concerns about its current performance and market sentiment.
  • Trading volume has been lower than average, which could indicate reduced investor interest and potential liquidity issues.
  • CSL Limited operates in a highly competitive industry, which may pose risks to its market share and profitability.
  • Recent fluctuations in stock price may suggest volatility, which could be a concern for risk-averse investors.
  • As a company heavily reliant on regulatory approvals for its products, any delays or rejections could negatively impact its financial performance.

CSLLY Forecast - Frequently Asked Questions

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CSL in the last twelve months. There is currently 1 sell rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CSLLY shares.

According to analysts, CSL's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, CSL's stock had 1 downgrade by analysts.

CSL has been rated by research analysts at Zacks Research in the past 90 days.

Analysts like CSL more than other "medical" companies. The consensus rating for CSL is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CSLLY compares to other companies.


This page (OTCMKTS:CSLLY) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners